Sie können Operatoren mit Ihrer Suchanfrage kombinieren, um diese noch präziser einzugrenzen. Klicken Sie auf den Suchoperator, um eine Erklärung seiner Funktionsweise anzuzeigen.
Findet Dokumente, in denen beide Begriffe in beliebiger Reihenfolge innerhalb von maximal n Worten zueinander stehen. Empfehlung: Wählen Sie zwischen 15 und 30 als maximale Wortanzahl (z.B. NEAR(hybrid, antrieb, 20)).
Findet Dokumente, in denen der Begriff in Wortvarianten vorkommt, wobei diese VOR, HINTER oder VOR und HINTER dem Suchbegriff anschließen können (z.B., leichtbau*, *leichtbau, *leichtbau*).
Cervical cancer represents an important global public health problem. It is the 2nd most common cancer among women worldwide. Human Papillomavirus (HPV) infection is now well-established as a necessary cause of invasive cervical cancer (ICC) development. Only a few studies on HPV prevalence and type-specific distribution in ICC have been conducted in Italy.
Aim
To describe the prevalence of HPV and the HPV type-specific distribution in ICC cases identified in Rome, Italy.
Methods
140 paraffin embedded tissue blocks of primary ICC diagnosed between 2001 and 2006 were identified at the Regina Elena Cancer Institute in Rome (Italy). HPV was detected through amplification of HPV DNA using SPF-10 HPV broad-spectrum primers followed by DEIA and then genotyping by LiPA25 (version 1).
Results
134 cases were considered suitable for HPV DNA detection after histological evaluation; and overall, 90.3% (121/134) HPV prevalence was detected. 111 cases had a single HPV type, 4 cases had an uncharacterized type (HPVX) and 6 cases had multiple HPV infections. The five most common single HPV types among positive cases were: HPV16 (71/121; 58.7%), HPV18 (12/121; 9.9%), HPV31, HPV45 and HPV58 (5/121; 4.1% each). 2 (1.5%) of the single infections and 2 (1.5%) of the multiple infections contained low risk types. Statistically significant differences in the relative contribution of HPV18 were found when comparing squamous cell carcinomas with adenocarcinomas.
Conclusions
HPV16 and HPV18 accounted for almost 70% of all the HPV positive ICC cases. The study provides baseline information for further evaluation on the impact of recently introduced HPV vaccines in Italy.
The online version of this article (doi:10.1186/1471-2407-10-259) contains supplementary material, which is available to authorized users.
Competing interests
Partial support has been obtained from Spanish public grants from the Instituto de Salud Carlos III (grants FIS PI030240, FIS PI061246, RCESP C03/09, RTICESP C03/10, RTIC RD06/0020/0095 and CIBERESP), from the Agència de Gestió d' Ajuts Universitaris i de Recerca (AGAUR 2005SGR 00695), the Marató de TV3 Foundation (051530), and from GlaxoSmithKline Biologicals, Sanofi Pasteur MSD & Merck & Co, Inc., who had no role in the data collection, analysis, or interpretation of the results.
Authors' contributions
LM, EV, FM, AV and MB were responsible for the specimens' selection. BLL was responsible for the pathology evaluation. JK and WQ were responsible for the HPV DNA detection and quality control analysis. BQ, LA, and NM were responsible for the data analysis. NM, LA and SdS contributed to the writing of the manuscript and LM, NM and LA were responsible for the preparation of the manuscript for submission. XFB and SdS planned the international collaborative project on HPV in invasive cervical cancer (ICO survey-RIS HPV TT). All authors read and approved the final manuscript.
Background
Cervical cancer is a serious public health problem representing the 2nd most common cancer diagnosed among women worldwide. Around 493,000 new cases and 274,000 deaths from this disease were estimated in 2002 [1]. In this study we analyse and present data regarding Human Papillomavirus (HPV) in invasive cervical cancer (ICC) specimens from Italy, a country whose population consist of 25.94 million [2] women at risk of developing ICC (15 y.o. or older). The age-standardized incidence rate of cervical cancer in Italy has been estimated at 8.1 new cases per 100,000 women annually [1]. Current estimates indicate that 3,418 women are diagnosed with ICC every year and 1,186 die from the disease, ranking the 10th most frequent cancer in women, however, the 3rd most frequent cancer in women between 15 and 44 years old [1].
HPV infection is now well-established as necessary but not sufficient cause of ICC development [3‐5]. Only a small fraction of women with cervical HPV infection develop ICC, suggesting that other co-factors besides HPV are necessary to cause cancer progression [6]. More than 30 different HPV types are known to infect the cervical epithelium [7, 8]. They have been classified into different groups according to their oncogenic potential in ICC: established low-risk types (HPV6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81 and 89), probable high-risk types (HPV26, 53, 66, 68, 73 and 82) and established high-risk types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59) [6, 9]. Data from an updated meta-analysis conducted by the International Agency for Research on Cancer (IARC) [10, 11] confirmed HPV16 as the most common type detected in ICC specimens worldwide, followed by HPV18, together accounting for 70% of the HPVs identified in ICC specimens. After HPV16/18, the next 6 most common HPV types were found to be the same in all world regions (HPV45, 31, 33, 52, 58, and 35), with only slight differences in their relative frequency over continents but, nevertheless, accounting for an additional 20% of cervical cancers worldwide [10, 11].
Anzeige
Very few studies on HPV type prevalence and type-specific distribution in ICC have been conducted in Italy [12‐17]. Thus, the main aim of this study was not only to present HPV prevalence but also to describe HPV type distribution in ICC specimens from Italy. This study is part of a larger project (Catalan Institute of Oncology-ICO survey) that aims to describe the HPV type-specific distribution in ICC specimens from areas with limited information available using standardized protocols.
Methods
Study design and materials
A cross sectional period-prevalence study on archival paraffin embedded ICC specimens was performed. 140 consecutively selected paraffin embedded tissue blocks with ICC from women diagnosed between 2001 and 2006 were identified and retrieved from the Regina Elena Cancer Institute in Rome, Italy. Age at diagnosis and year of diagnosis were collected from medical records.
Pathology and laboratory procedures: Paraffin blocks processing, histopathological evaluation, HPV DNA detection and typing
Selecting the paraffin blocks and microtome sectioning was performed in Rome, under strict conditions to avoid potential contamination and following a protocol previously developed at ICO. Briefly, at least four paraffin sections were obtained for each block ("sandwich" method). First and last microtome sections were stained with Haematoxylin and Eosin (H&E) for histopathological evaluation. The sections that were cut in-between the two H&E slides were collected in two eppendorf type tubes for HPV DNA testing (one tube for initial testing and the other for back-up). A tissue-free paraffin block was cut after each study block to avoid HPV carry-over from block to block. A new blade was used for each study block, and the microtome was cleaned with Histoclear II, a xylene substitute, and 70% alcohol. Paraffin blocks containing non HPV-related lesions, such as, non HPV-related tumours or non-tumour biopsies were blindly included and analyzed as controls in the process for further quality control of laboratory results.
The pathology classification of the histopathological diagnosis was done at ICO following the consensus criteria established by an expert panel of collaborating pathologists. These criteria were based on the World Health Organization (WHO) classification of uterine cervix tumours [18]. The pathology evaluation included: diagnosis of histological type (ICC: -squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, other types-; non-invasive cervical cancer and control tissue specimen); presence of normal mucosa or pre-neoplastic lesions adjacent to ICC (Cervical Intraepithelial Neoplasia - CIN1, 2, or 3; Adenocarcinoma in Situ-AIS); degree of necrosis; tumour infiltration expressed by % (quantity of necrosis/infiltrating component of the tumour in the total of the section), and adequacy of the sample to proceed to HPV testing. A sample was determined to be adequate for HPV analysis if invasive cancer was observed on both H&E stained sections of the study specimen.
Anzeige
DNA isolation was performed by treating the cut sections of paraffin embedded tissues with 250 μl of freshly prepared 0.1% proteinase K solution (5 mM Tris HCl, 0.1 mM EDTA, 0.05% Tween 20). The samples were incubated at 56°C for 18 hours to overnight. Proteinase K was then heat inactivated at 95°C for 10 minutes. Short Polymerase Chain Reaction Fragment - using biotin labelled SPF-10 primers [19, 20] was performed using 10 μl of a 1:10 dilution of the crude DNA isolate in a final reaction volume of 50 μl. Presence of HPV DNA, was determined by a probe hybridization technique that contains a mixture of HPV specific probes recognizing at least 54 mucosal HPV genotypes in a microtiter plate format (DNA Enzyme Immuno Assay -DEIA). Briefly, 10 μl of the PCR product was incubated in a hybridization buffer in a streptavidin-coated microtiter plates. The plates were washed and the captured PCR product was denatured using NaOH. Subsequently, digoxigenin (DIG)-labelled HPV-specific probes were added and following incubation, the plates were washed 3 times. Finally, an anti-DIG alkaline phosphatase substrate was added to the wells and after a short incubation time, the optical densities were determined. Optical densities (OD450) were read on a microtiter plate reader (Bio-tek) [19]. For genotyping HPV DNA, 10 μl of the PCR amplimers of the HPV DNA positive samples, as identified by DEIA, were analyzed by Line Probe Assay-LiPA25 version 1. (Labo Biomedical Products, Rijswijk, The Netherlands), that can detect 25 different high-risk and low-risk HPV types (6, 11, 16, 18, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 70, 74). The sequence variation within the SPF-10 primers allows the recognition of these different HPV genotypes, except for types 68 and 73, as their interprimer regions are identical and cannot be distinguished by this test. Positive hybridization on the strips is visualized as a purple band by means of a precipitating colour substrate on the probe site. Specimens that were identified as HPV DNA positive, but did not hybridize with any of the 28 LiPA probes patterns, were coded as HPV type X (uncharacterized type). SPF-10 PCR, detection and typing were performed at ICO.
Statistical analysis
Data analysis was performed with the Statistical Package SPSS 14.0. Overall and type-specific HPV prevalence (within the total of samples analyzed) and type-specific relative contribution (within the HPV positive cases) were analyzed and 95% confidence intervals (95% CIs) for proportions were calculated. To estimate the HPV type distribution, single and multiple HPV infections were considered either separately or combined. Stratified analyses of overall HPV and type-specific distributions by age at diagnosis and histological characteristics were performed. Age was recoded as a categorical variable (≤39, 40-49, 50-59, and ≥60 years). Statistical significance for two sided chi-squared and linear trend tests were set at 0.05 levels [21].
Ethical issues
Specimens were received at the reference laboratory in Barcelona (ICO) under an anonymous manner (without name and/or original medical record number nor histology report). All protocols were approved by local and ICO ethical committees. The study's progress was overseen by an international steering committee specifically created for the supervision and to act as an advisory committee for handing critical ethics as well as scientific issues of the project.
Results
After histological evaluation, 134 ICC specimens from the original 140 cases were considered suitable for HPV testing; 6 specimens were excluded because they were classified as non-invasive cervical cancers. Mean age of HPV analyzed cases was 52.4 years (Standard Deviation: 14.2; minimum 23 years, maximum value 85 years). Squamous cell carcinoma was the most frequent histological type (83.6%), followed by adenocarcinoma (12.7%) and adenosquamous cell carcinoma (0.8%). Other histopathological types accounted for 3.0%, and were classified as 2 undifferentiated carcinomas, 1 poorly differentiated large cell carcinoma and 1 basal adenoid carcinoma. Microscope slides were systematically reviewed by the pathologists to identify characteristics that could affect detection such as grade of necrosis, tumour infiltration, concomitant lesions or if mucosa was associated. Table 1 describes the different parameters that were evaluated without considering HPV status. The majority of specimens (89.6%) had a low percentage of necrotic cells (grade of necrosis was below 25%). Tumour infiltration under 25% was rarely seen (6.0%). 81.3% of cases had no pre-invasive lesion associated: CIN I was identified in only one HPV positive case, CIN III was observed in 22 cases (16.4%) and AIS lesions were found in 4 cases (3.0%), two of which were concomitant with a CIN III lesion. Almost two thirds of the series had no associated mucosa (66.4%). There were no major differences in HPV positivity by age at diagnosis and histological features evaluated, as shown in Table 1.
Table 1
Detection of HPV DNA in ICC specimens from Italy, by age at diagnosis and histopathological information
HPV analyzed cases (n)
HPV positive cases (n)
HPVprevalence % (95% CI)
Age (years)
≤39
29
25
86.2 (68.7-96.1)
40-49
36
35
97.2 (85.5-99.9)
50-59
27
25
92.6 (75.7-99.1)
≥60
42
36
85.7 (71.5-94.6)
Histological type
Squamous cell carcinoma
112
101
90.2 (83.1-95.0)
Adenocarcinoma
17
16
94.1 (71.3-99.8)
Adenosquamous cell carcinoma
1
1
100.0 (25.0-100.0)
Other
4
3
75.0 (19.4-99.4)
Degree of Necrosis
<25%
120
110
91.7 (85.2-95.9)
25%-50%
12
11
91.7 (61.5-99.8)
51%-75%
2
0
0.0 (0.0-84.2)
Tumour Infiltration
<10%
1
1
100.0 (25.0-100.0)
10%-25%
7
6
85.7 (42.1-99.6)
26%-50%
43
38
88.4 (74.9-96.1)
51%-75%
41
39
95.1 (83.5-99.4)
>75%
42
37
88.1 (74.4-96.0)
Mucosa
Squamous mucosa
15
14
93.3 (68.0-99.8)
Endocervical mucosa
10
9
90.0 (55.5-99.7)
Squamous and endocervical mucosa
20
18
90.0 (68.3-98.8)
No mucosa
89
80
89.9 (81.7-95.3)
CIN III (*)
Yes
22
20
90.9 (70.8-98.9)
No
112
101
90.2 (83.1-95.0)
AIS (**)
Yes
4
4
100.0 (39.8-100)
No
130
117
90.0 (83.5-94.6)
Total
134
121
90.3 (84.0-94.7)
(*) CIN III: Cervical Intraepithelial Neoplasia III - Adjacent to ICC.
(**) AIS: Adenocarcinoma in Situ - Adjacent to ICC.
95% CI: 95% Confidence Interval.
Data on HPV testing and typing is summarized in Table 2. 121 of 134 specimens were HPV DNA positive (90.3%; 95% CI: 84.0%-94.7%). Among the HPV positive cases, 111 were identified as single HPV types (91.7%), 4 were HPVX (3.3%) and 6 harboured multiple HPV types (5.0%). The five most common single types among positive cases were: 71 HPV16 (58.7%), 12 HPV18 (9.9%) and 5 of each HPV31, HPV45 and HPV 58 (4.1%). Multiple infection combinations were: HPV16&18, HPV45&51, HPV31&42, HPV31&52, HPV6&53&66 and HPV53&56&58. In two cases, exclusively low risk types were identified, one HPV42 and one HPV70 as single infections. These were repeated at least twice, and in both occasions showed strong hybridization patterns at the probe sites. HPV6 and HPV42 also were harboured in two multiple infections (HPV6&53&66, HPV31&42).
Table 2
Distribution of HPV types in ICC specimens from Italy
(***) Considering a 100% vaccine efficacy (without cross-protection).
95% CI: 95% Confidence Interval.
HPV16 relative contribution was higher in squamous cell carcinoma (62.4%) than in adenocarcinoma (43.8%) with HPV16 as the most frequent type identified in both (p > 0.05). HPV18 was more prevalent in adenocarcinomas (31.3%) than in squamous cell carcinomas (5.0%) (p < 0.05). HPV31, HPV45 and HPV58 single infections were as frequent as HPV18 in squamous cell carcinoma (5.0%) (Figure 1).
Figure 1
HPV type distribution among ICC HPV positive cases, regarding histology.
The relative contribution of HPV16 was inversely related to increasing age. Nearly 72% HPV16 single types were identified within the youngest age group (<40 years), 57% in the 40-49 years group and 54% in women older than 49 years; although these differences were not statistically significant, p-trend test >0.05.
Discussion
In the present study a high proportion (90.3%) of the ICC specimens analyzed was HPV DNA positive. HPV16 and HPV18 together accounted for 69.4% of the HPV positive cases. Types HPV31, HPV45, HPV58 and HPV33 also were identified with no major distinction between them in terms of relative importance. Collectively, these types accounted for an additional 15.6% of single infections.
Anzeige
Several meta-analyses on HPV detection among ICC have been published by IARC [10, 11] presenting an overall HPV prevalence by geographical area ranging from 79.3% in Asia to 88.1% in North America. In published data updated in 2007 [11], the HPV positivity increased to 87% (ranging from 86% to 94% by region). These variations or the increase of the HPV positivity could be explained by the differences on the methodologies used to determine HPV DNA positivity, histopathologic quality of the samples and the type of specimens analyzed (biopsies, surgical specimens, fresh/frozen tissue samples). The overall HPV positivity in our study was even slightly higher given that a highly sensitive PCR technology was used [19] along with a prior examination of the tissue sections by pathologists to ensure the quality of the specimens before continuing onto testing.
3,607 women with incident and histological confirmed cervical cancer recruited in 25 countries were used for a pooled analysis of data in an international survey of cervical cancer HPV types and a multicenter case-control study, both co-coordinated by the IARC [22]. The study published the two most common HPV types as follows: 57.4% prevalence for HPV16 (from 52% in Asia to 58% in Europe) and 16.6% prevalence for HPV18 (from 13% in South and Central America to 22% in North America). In our study HPV16 also was the most common type in ICC, with a prevalence of around 53%, in agreement with previous reports. Although HPV18 was the second most frequent type, its prevalence of approximately 9.0% in Italy was considerably lower compared with previous reports but still in agreement with previous studies conducted in Italy (Table 3) [12‐17]. Our data were in agreement regarding HPV16 prevalence with other studies conducted in Italy. Although based on small numbers, in our study we observed HPV58 to be as prevalent as HPV45, which was consistent with previous observations [10, 11]. Moreover, when compared with data from the WHO/ICO HPV information centre for ICC (Table 4), in neighbouring regions and countries, HPV16 and 18 almost were first and second HPV types in frequency position, followed by HPV31, 33, 45, 51 and 52 with slightly prevalence variation [23].
Table 3
Comparison of HPV prevalence in ICC specimens among studies conducted in Italy
M.I.: Multiple infections. A multiple infection is counted once on every type involved. In example: HPV16&74 is counted as n = 1 in HPV16 and n = 1 in HPV74. The sum of the total % may exceed 100%.
Gioele G. Garzetti et al.: Histology: 32 patients with FIGO Stage I and IIA SCC who had undergone primary radical hysterectomy and bilateral oophorectomy. Patients with no SCC histotype were excluded. M.I.: HPV16&31.
Ciotti et al.: Histology: 102 SCC. M.I.: n = 4 HPV31&54; n = 3 HPV16&33; n = 3 HPV16&18; n = 1 HPV33&54; n = 1 HPV16&53. Other: n = 8 single infections (n = 3 HPV56; n = 2 HPV52, n = 1 HPV51, n = 1 HPV35, n = 1 HPV73) and n = 6 in M.I. (n = 4 HPV31&54, n = 1 HPV33&54, n = 1 HPV16&53).
Del Mistro et al.: Histology: 48 SCC (43 SCC and 5 Adenocarcinomas). M.I.: n = 5 (n = 3 HPV16&18; n = 1 HPV16&31; n = 1 HPV56&70).Other: n = 2 in single infections (n = 1 HPV35; n = 1 HPV52) and n = 2 in M.I: (n = 1 HPV56; n = 1 HPV70).
Tornesello et al.: 65 SCC. M.I.: n = 1 HPV16&73. Other: n = 3 single infections (n = 1 HPV35, n = 1 HPV62, n = 1 HPV82) and n = 1 M.I (HPV16&73).
Gargiulo et al.: Histology: 31 cervical cancer samples analyzed with non histological sub classification specified. M.I.: n = 14, already counted in Table 2 of the article. They do not specify all the M.I as some were up to more the 5 HPV types. Only the most prevalent ones are described. Other: n = 5 HPV52; n = 4 HPV61; n = 3 HPV70; n = 3 HPV84; n = 2 HPV51; n = 2 HPV62; n = 1 HPV35; n = 1 HPV39; n = 1 HPV56; n = 1 HPV53; n = 1 HPV55; n = 1 HPV66; n = 1 HPV67; n = 1 HPV81; n = 1 HPV89.
Present study: Histology: 134 samples (122 SCC, 17 Adenocarcinomas, 1 adenosquamous and 4 other histological types). M.I.: n = 6 (n = 1 HPV16&18; n = 1 HPV45&51; n = 1 HPV31&42; n = 1 HPV31&52; n = 1 HPV6&53&66; n = 1 HPV53&56&58). Other: n = 9 in single infections (n = 2 HPV35; n = 2 HPV51; n = 2 HPV52; n = 1 HPV42; n = 1 HPV56; n = 1 HPV70) and n = 8 in M.I (n = 2 HPV53; n = 1 HPV51; n = 1 HPV52; n = 1 HPV42; n = 1 HPV6; n = 1 HPV66; n = 1 HPV56).
Table 4
The five most common HPV types (HPV type-specific prevalence) in ICC specimens for any histology: Worldwide, Europe, Southern Europe region and neighbourhood European countries
HPV Position
Italya
Worldb
Europeb
Southern Europeb
Austriab
Croatiab
Franceb
Germanyb
Greeceb
Spainb
1st
HPV16
(53.7%)
HPV16
(54.4%)
HPV16
(57.7%)
HPV16
(48.5%)
HPV16
(70.0%)
HPV16
(45.0%)
HPV16
(60.7%)
HPV16
(58.0%)
HPV16
(22.2%)
HPV16
(51.0%)
2nd
HPV18
(9.7%)
HPV18
(16.5%)
HPV18
(16.8%)
HPV18
(13.6%)
HPV33
(21.5%)
HPV18
(36.9%)
HPV18
(14.9%)
HPV18
(18.8%)
HPV18
(19.1%)
HPV31
(5.3%)
3rd
HPV31
(5.2%)
HPV58
(5.1%)
HPV33
(4.3%)
HPV31
(6.5%)
HPV18
(8.5%)
HPV51
(17.6%)
HPV31
(3.8%)
HPV52/68
(5.6%)
HPV6
(3.8%)
HPV18
(4.9%)
4th
HPV45/58
(4.5%)
HPV33
(4.7%)
HPV31
(4.1%)
HPV33
(4.9%)
HPV45
(4.5%)
HPV31/33
(11.7%)
HPV33/68
(3.3%)
HPV31
(2.9%)
HPV51
(2.9%)
HPV45
(4.1%)
5th
HPV33
(3.0%)
HPV45
(4.4%)
HPV45
(3.5%)
HPV45
(3.3%)
HPV31
(4.0%)
HPV45
(2.7%)
HPV45
(2.9%)
HPV35
(1.4%)
HPV33
(2.8%)
HPV33
(3.0%)
a) Data for Italy: extracted from the present study.
b) Source of information: WHO/ICO Information Centre on Human Papillomavirus (HPV) and Cervical Cancer http://www.who.int/hpvcentre/statistics/en/ (ref.[23]); Selection of regions: World, Europe, Southern Europe (Albania, Andorra, Bosnia & Herzegovina, Croatia, Greece, Italy, Macedonia, TFYR, Malta, Montenegro, Portugal, San Marino, Serbia, Slovenia, Spain), and neighbourhood European countries; No data available for: Bosnia & Herzegovina, Montenegro, Slovenia and Switzerland.
Methods for counting HPV type-specific prevalence: HPV single and multiple infections counted once in each HPV type; prevalence: HPV positive cases for a specific HPV type among HPV analyzed cases.
The association between HPV type and histological type has been described in a large number of studies [10, 11]. Tenti et al. reported a slightly higher prevalence of HPV18 (29.7%) than HPV16 (28.3%) in a study conducted in Italy on 138 adenocarcinomas of the cervix [12]. Similarly, in the present study HPV16 was shown to be more common in squamous cell carcinomas whereas HPV18 was more common in adenocarcinomas.
Even though a high-sensitive HPV DNA PCR based technology was used for detection and HPV typing (SPF-10-LiPA25), our study is not without some limitations. Sample collection was available from only one hospital in Italy (the Regina Elena National Cancer Institute of Rome). Although the number of samples analyzed is limited and obviously not representative of the whole country, they were originated from a systematic collection at a national cancer reference centre providing a potential good representation of all cases in the country.
Anzeige
Conclusions
Our data is in good agreement with previously published information and indicate that a HPV vaccine targeting HPV types 16 and 18 could potentially prevent 70% of HPV positive cervical cancers. The earlier age at diagnosis of most HPV 16 related cancers may have implications in future strategies of prevention in adult women.
Acknowledgements
We are grateful to the work of all the ICO survey-RIS HPV TT collaborators and the Steering Committee members. The study is part of the international study RIS HPV TT coordinated at ICO, Barcelona, Spain. The authors would like to thank Dr Eric J Duell for assistance with manuscript editing, as well as Fancesca Rollo.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Competing interests
Partial support has been obtained from Spanish public grants from the Instituto de Salud Carlos III (grants FIS PI030240, FIS PI061246, RCESP C03/09, RTICESP C03/10, RTIC RD06/0020/0095 and CIBERESP), from the Agència de Gestió d' Ajuts Universitaris i de Recerca (AGAUR 2005SGR 00695), the Marató de TV3 Foundation (051530), and from GlaxoSmithKline Biologicals, Sanofi Pasteur MSD & Merck & Co, Inc., who had no role in the data collection, analysis, or interpretation of the results.
Authors' contributions
LM, EV, FM, AV and MB were responsible for the specimens' selection. BLL was responsible for the pathology evaluation. JK and WQ were responsible for the HPV DNA detection and quality control analysis. BQ, LA, and NM were responsible for the data analysis. NM, LA and SdS contributed to the writing of the manuscript and LM, NM and LA were responsible for the preparation of the manuscript for submission. XFB and SdS planned the international collaborative project on HPV in invasive cervical cancer (ICO survey-RIS HPV TT). All authors read and approved the final manuscript.
Ferlay J, Bray F, Pisani P, Parkin DM: Globocan 2002 cancer incidence, mortality and prevalence worldwide. 2004, Lyon: IARC Press, IARC Cancer Base No.5 version 2.0
2.
Castellsagué X, de Sanjosé S, Aguado T, Louie KS, Bruni L, Muñoz J, Diaz M, Irwin K, Gacic M, Beauvais O, Albero G, Ferrer E, Byrne S, Bosch FX: HPV and Cervical Cancer in the World. 2007 Report. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Vaccine. 2007, 25 (S3): C110-
3.
Muñoz N, Bosch FX, de Sanjose S, Tafur L, Izarzugaza I, Gili M, Viladiu P, Navarro C, Martos C, Ascunce N, Gonzalez LC, Kaldor JM, Guerrero E, Lorincz A, Santamaria M, Alonso De Ruiz P, Aristizabal N, Shah K: The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain. Int J Cancer. 1992, 52: 743-749. 10.1002/ijc.2910520513.CrossRefPubMed
4.
Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV: Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995, 87: 796-802. 10.1093/jnci/87.11.796.CrossRefPubMed
5.
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999, 189: 12-19. 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F.CrossRefPubMed
6.
Muñoz N, Castellsagué X, Berrington A, Gissmann L: Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006, 24S3: S3/1-S3/10.
7.
Bernard HU: The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses. J Clin Virol. 2005, 32 (suppl 1): S1-S6. 10.1016/j.jcv.2004.10.021.CrossRefPubMed
8.
Doorbar J: Molecular biology of human papillomavirus infection and cervical cancer. Clinical Science. 2006, 110: 525-541. 10.1042/CS20050369.CrossRefPubMed
9.
Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ, International Agency on Cancer Multicenter Cervical Cancer Study Group: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003, 348: 518-527. 10.1056/NEJMoa021641.CrossRefPubMed
10.
Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S: Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003, 88: 63-73. 10.1038/sj.bjc.6600688.CrossRefPubMedPubMedCentral
11.
Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM: Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007, 121: 621-632. 10.1002/ijc.22527.CrossRefPubMed
12.
Tenti P, Romagnoli S, Silini E, Zappatore R, Spinillo A, Giunta P, Cappellini A, Vesentini N, Zara C, Carnevali L: Human papillomavirus types 16 and 18 infection in infiltrating adenocarcinoma of the cervix: PCR analysis of 138 cases and correlation with histologic type and grade. Am J Clin Pathol. 1996, 106 (1): 52-56.CrossRefPubMed
13.
Garzetti GG, Ciavattini A, Lucarini G, Goteri G, Menso S, De Nictolis M, Romanini C, Biagini G: The role of human papillomavirus DNAs in cervical carcinoma and risk of lymph node metastasis: association with 72-kilodalton metalloproteinase immunostaining. Cancer. 1998, 82 (5): 886-892. 10.1002/(SICI)1097-0142(19980301)82:5<886::AID-CNCR13>3.0.CO;2-X.CrossRefPubMed
14.
Ciotti M, Paba P, Bonifacio D, Di Bonito L, Benedetto A, Favalli C: Single or multiple HPV types in cervical cancer and associated metastases. Oncol Rep. 2006, 15 (1): 143-148.PubMed
15.
Del Mistro A, Salamanca HF, Trevisan R, Bertorelle R, Parenti A, Bonoldi E, Zambon P, Minucci D: Human papillomavirus typing of invasive cervical cancers in Italy. Infect Agent Cancer. 2006, 27: 1-9.
16.
Tornesello ML, Duraturo ML, Botti G, Greggi S, Piccoli R, De Palo G, Montella M, Buonaguro L, Buonaguro FM, Italian HPV Working Group: Prevalence of alpha-papillomavirus genotypes in cervical squamous intraepithelial lesions and invasive cervical carcinoma in the Italian population. J Med Virol. 2006, 78 (12): 1663-1672. 10.1002/jmv.20752.CrossRefPubMed
17.
Gargiulo F, De Francesco MA, Schreiber C, Ciravolo G, Salinaro F, Valloncini B, Manca N: Prevalence and distribution of single and multiple HPV infections in cytologically abnormal cervical samples from Italian women. Virus Res. 2007, 125 (2): 176-182. 10.1016/j.virusres.2006.12.017.CrossRefPubMed
18.
Tavassoli FA, Devilee P: World Health Organization Classification of Tumours Pathology and Genetics of Tumours of the Breast and Female Genital Organs. 2003, IARC Press: Lyon
19.
Kleter B, van Doorn LJ, Ter Schegget J, Schrauwen L, Van Krimpen K, Burger M, ter Harmsel B, Quint W: Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human Papillomaviruses. Am J Pathol. 1998, 153: 1731-1739.CrossRefPubMedPubMedCentral
20.
Kleter B, van Doorn LJ, Schrauwen L, Molijn A, Sastrowijoto S, ter Schegget J, Lindeman J, ter Harmsel B, Burger M, Quint W: Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol. 1999, 37: 2508-2517.PubMedPubMedCentral
21.
Breslow NE, Day NE: Statistical methods in cancer research. Vol. I -The analysis of case-control studies. 1980, IARC Sci Publ, Lyon
22.
Muñoz N, Bosch FX, Castellsagué X, Díaz M, De Sanjosé S, Hammouda D, Shah HV, Meijer CJ: Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004, 111: 278-285. 10.1002/ijc.20244.CrossRefPubMed
Die Prognose beim inflammatorischen Mammakarzinom bleibt ungünstig, wie eine Analyse von US-Registerdaten nahelegt. Ein weiteres Problem ist demnach, dass zunehmend weniger Frauen die leitliniengerechte trimodale Therapie erhalten.
Bei einem nach Radiotherapie lokal rezidivierten Prostatakarzinom sind fokale Salvage-Therapien mit einer guten Prognose verbunden: Das krebsspezifische Zehn-Jahres-Überleben ist einem retrospektiven Vergleich zufolge ebenso hoch wie nach Salvage-Prostatektomie.
Durch Hinzunahme des Glukokortikoid-Rezeptor-Antagonisten Relacorilant zu nab-Paclitaxel wird bei Frauen mit platinresistentem Ovarialkarzinom nicht nur das progressionsfreie, sondern auch das Gesamtüberleben verlängert. Laut finaler Analyse der ROSELLA-Studie gewinnen sie vier Monate an Lebenszeit.
Immunvermittelte Hautreaktionen gehören zu den häufigsten Nebenwirkungen von Immun‑Checkpoint‑Inhibitoren. Eine offene Phase‑2‑Studie untersuchte den JAK‑1‑Inhibitor Upadacitinib bei schwerer ICI‑assoziierter Dermatitis. Die Hautsymptome gingen rasch zurück, schwerwiegende therapieassoziierte Nebenwirkungen wurden nicht beobachtet.
